Pembrolizumab en première ligne thérapeutique dans les cancers colorectaux métastatiques présentant une instabilité microsatellitaire élevée MSI
- 23 February 2021
- journal article
- letter
- Published by Elsevier BV in Bulletin du Cancer
- Vol. 108 (3), 229-231
- https://doi.org/10.1016/j.bulcan.2021.01.004
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal CancerThe New England Journal of Medicine, 2020
- Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor typesCancer Medicine, 2020
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 StudyJournal of Clinical Oncology, 2020
- Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency StatusJAMA Oncology, 2019
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal CancerJournal of Clinical Oncology, 2018
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience, 2017